Bank Of America Corp Alaunos Therapeutics, Inc. Transaction History

Bank Of America Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.04 - $0.13 $617 - $2,005	-15,427 Reduced 21.09%	57,728 $4,000
Q2 2023 Aug 14, 2023	BUY	$0.43 - $0.65 $7,045 - $10,650	16,386 Added 28.86%	73,155 $37,000
Q1 2023 May 12, 2023	SELL	$0.46 - $0.81 $4,458 - $7,850	-9,692 Reduced 14.58%	56,769 $35,000
Q4 2022 Feb 10, 2023	SELL	$0.5 - $261.0 $97,405 - $50.8 Million	-194,811 Reduced 74.56%	66,461 $43,000
Q3 2022 Nov 14, 2022	BUY	$1.04 - $322.5 $253,996 - $78.8 Million	244,227 Added 1432.84%	261,272 $449,000
Q2 2022 Aug 12, 2022	SELL	$0.41 - $1.24 $19,632 - $59,374	-47,883 Reduced 73.75%	17,045 $21,000
Q1 2022 May 16, 2022	SELL	$0.62 - $1.17 $470,330 - $887,559	-758,598 Reduced 92.12%	64,928 $43,000
Q4 2021 Feb 08, 2022	BUY	$1.09 - $1.89 $431,770 - $748,666	396,120 Added 92.68%	823,526 $897,000
Q3 2021 Nov 15, 2021	BUY	$1.44 - $2.73 $51,164 - $96,999	35,531 Added 9.07%	427,406 $778,000
Q2 2021 Sep 13, 2021	BUY	$2.63 - $3.67 $1.03 Million - $1.44 Million	391,875 New	391,875 $1.04 Million

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $458M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.